1.	Open-label Study of CS1008 for Subjects With Untreated and Unresectable Pancreatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CS1008-A-U201, NCT00521404
2.	Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CS1008-A-U205, NCT00945191
3.	CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CS1008-A-E202, NCT00991796
4.	CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CS1008-A-U204, NCT01033240
5.	Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over (19 in Alabama) Sponsor: Other Protocol IDs: F101004001 (UAB1028), TBCRC 019, NCT01307891
6.	Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CS1008-A-U101, NCT00320827
7.	Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CS1008-A-U105, NCT01124630